In a development that could fundamentally reshape the landscape of obesity treatment, researchers at Stanford Medicine have identified a naturally occurring molecule that mimics the appetite-suppressing benefits of blockbuster weight-loss drugs like semaglutide (the active ingredient in Ozempic and Wegovy) while potentially sidestepping the uncomfortable, and often debilitating, side effects associated with current therapies.
The molecule, dubbed "BRP" (BRINP2-related-peptide), was discovered through a sophisticated application of artificial intelligence. In preclinical trials involving animal models, BRP has demonstrated a remarkable ability to induce weight loss while avoiding the nausea, digestive complications, and loss of lean muscle mass that frequently plague patients on GLP-1 receptor agonists.
The Main Facts: A New Mechanism of Action
The central challenge with current weight-loss medications like semaglutide is their systemic nature. Because the receptors targeted by GLP-1 drugs are distributed throughout the gut, pancreas, and other tissues, the treatment often causes widespread physiological impacts. While effective at curbing hunger, this systemic interference is precisely what leads to common side effects such as constipation, slowed digestion, and nausea.
BRP operates under a different paradigm. According to the study published March 5 in the journal Nature, BRP targets a distinct metabolic pathway, focusing its activity almost exclusively on the hypothalamus. This deep-brain region serves as the body’s master control center for appetite, energy expenditure, and hormonal regulation. By confining its effects to this precise location, BRP appears to suppress appetite without the "off-target" effects that burden the rest of the body’s organ systems.
Chronology of Discovery: From Big Data to Biological Breakthrough
The discovery of BRP was not a product of chance, but of a deliberate, AI-driven hunt for "hidden" biological signals.
The Search for Hidden Peptides
For years, the scientific community has known that "prohormones"—inactive precursor molecules—must be cleaved by enzymes into smaller fragments called peptides before they can perform their biological functions. However, identifying which of these thousands of fragments are actually potent hormones has been a "needle in a haystack" problem. Traditional laboratory techniques, such as mass spectrometry, often generate insurmountable volumes of data, making it nearly impossible to filter out background noise.
The Development of "Peptide Predictor"
The Stanford team, led by assistant professor of pathology Katrin Svensson, PhD, and senior research scientist Laetitia Coassolo, PhD, bypassed these manual limitations by developing a custom computer algorithm named "Peptide Predictor."
- Filtering the Human Genome: The algorithm scanned all 20,000 human protein-coding genes for specific cleavage sites—sequences where enzymes typically cut proteins.
- Focusing the Scope: The researchers narrowed their search to genes that produce proteins secreted outside the cell, a hallmark of hormonal activity.
- Refining the Candidates: This process reduced the potential field of study from thousands of variables to 373 promising prohormones.
- The Final Cut: The algorithm estimated that these 373 proteins could produce 2,683 distinct peptides. The team focused on those most likely to impact the brain, ultimately selecting 100 peptides to test in laboratory neuron cultures.
The "Aha!" Moment
During initial testing, the known peptide GLP-1 performed as expected, stimulating neuronal activity to three times the level of control cells. However, a tiny, 12-amino-acid peptide—derived from the prohormone BRINP2—produced a tenfold increase in neuronal activity. This peptide was christened BRP.
Supporting Data: Efficacy in Animal Models
The leap from lab-grown cells to animal models provided the most compelling evidence of BRP’s potential. In both lean mice and minipigs—the latter of which share significant metabolic similarities with humans—an intramuscular injection of BRP reduced food intake by up to 50% within the hour following administration.
In a 14-day trial involving obese mice, the results were even more encouraging:
- Targeted Weight Loss: Treated mice lost an average of 3 grams, with nearly the entire loss attributed to body fat rather than muscle. In contrast, the control group gained 3 grams over the same period.
- Metabolic Health: Beyond weight loss, the treated subjects exhibited improved glucose and insulin tolerance, suggesting that the peptide helps restore the body’s ability to process blood sugar efficiently.
- Absence of Adverse Behaviors: Crucially, behavioral assessments showed no negative impact on movement, water intake, or signs of anxiety. Unlike semaglutide, BRP did not cause changes in fecal production, indicating that it does not slow the digestive tract in the way existing GLP-1 therapies do.
Official Responses and Researcher Perspectives
The research team is acutely aware of the limitations of animal studies but remains optimistic about the molecule’s clinical trajectory.
"The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues," Dr. Svensson noted. "That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."
Regarding the scarcity of current options, Dr. Svensson added, "The lack of effective drugs to treat obesity in humans has been a problem for decades. Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."
To facilitate this, Dr. Svensson has co-founded a company, Merrifield Therapeutics, with the express intent of moving BRP into human clinical trials. The researchers are currently working to identify the specific cell-surface receptors that BRP binds to, a critical step in understanding the precise biochemical "handshake" that initiates weight loss.
Implications for the Future of Medicine
If BRP proves successful in human trials, the implications for global health would be profound. Obesity remains a primary driver of heart disease, type 2 diabetes, and various cancers. While the current generation of GLP-1 drugs has been revolutionary, their side-effect profile often leads to high patient drop-off rates.
Addressing the "Muscle Loss" Concern
One of the most significant advantages of BRP, as observed in the mouse models, is the preservation of muscle mass. A growing concern with rapid weight-loss medications is that patients are losing significant amounts of muscle alongside fat, which can lead to metabolic slowdown and frailty. If BRP can selectively target fat stores while sparing muscle, it would represent a "holy grail" for metabolic health.
The Challenge of Duration
One hurdle remains: the stability of the peptide. Small peptides are often metabolized and cleared by the body with high speed, requiring frequent dosing. The research team is currently investigating methods to extend the half-life of BRP, potentially through molecular modification or specialized delivery systems, to ensure it can be administered on a practical, patient-friendly schedule.
The AI Advantage
Finally, this study serves as a milestone for the role of artificial intelligence in drug discovery. By demonstrating that an algorithm could identify a therapeutic peptide that had previously been overlooked by decades of traditional research, Stanford has provided a blueprint for how AI might be used to decode the remainder of the human "peptidome."
As the team at Stanford moves toward clinical trials, the medical community will be watching closely. While the transition from mouse models to human patients is notoriously difficult, the precision of BRP’s mechanism—and the success of the AI that found it—suggests that the next generation of weight-loss therapies may be significantly more refined than those that came before.
The study was supported by a wide array of institutions, including the National Institutes of Health, the SPARK Translational Research Program at Stanford, and the Wu Tsai Human Performance Alliance. Researchers from UC Berkeley, the University of Minnesota, and the University of British Columbia also provided critical contributions.
